THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF ARTICLE 7 OF THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014
WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 ("UK MAR"). IN ADDITION, MARKET SOUNDINGS
WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS
ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF
SUCH INSIDE INFORMATION. UPON THE PUBLICATION OF THIS ANNOUNCEMENT,
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN AND SUCH PERSONS SHALL THEREFORE CEASE TO BE IN POSSESSION
OF INSIDE INFORMATION.
1 March 2024
Nuformix
plc
("Nuformix" or the "Company")
Subscription to raise
£150,000
Nuformix plc (LSE: NFX), a
pharmaceutical development company targeting unmet medical needs in
fibrosis and oncology via drug repurposing,
announces a subscription to raise gross proceeds of £150,000
through a subscription for 75,000,000 new ordinary shares of 0.1
pence in the capital of the Company (the "New Ordinary Shares") at
a price of 0.20 pence per share (the "Subscription").
The New Ordinary Shares will represent
approximately 9.2 per cent. of the Company's enlarged issued share
capital and are being issued pursuant to the Company's existing
share issuance authorities.
The net proceeds of the Subscription
will be used by the Company primarily to further advance its NXP002
programme for the inhaled treatment of idiopathic pulmonary
fibrosis ("IPF").
Commenting, Dr Dan Gooding, Executive Director of Nuformix,
said: "The funds raised through the Subscription will support the
Company as we focus on discussions with potential licensees and the
overall progression of the NXP002 programme to improve the
treatment of IPF via inhalation. I look forward to providing
further updates in due course."
Admission and Total Voting Rights
Application will be made for the
75,000,000 New Ordinary Shares to be admitted to the Official List
of the FCA and to trading on the Main Market of the London Stock
Exchange ("Admission"). It is expected that Admission will become
effective and that unconditional dealings will commence on the
London Stock Exchange at 8.00 a.m. on 6 March 2024.
Following Admission of the New
Ordinary Shares, the total number of Ordinary Shares in issue will
be 819,309.368, each with one voting right. The Company does
not hold any rights in treasury. The total voting rights
figure is therefore 819,309,368 and can be used by shareholders as
the denominator for the calculations by which they will determine
whether they are required to notify their interest in, or a change
of their interest in, the Company under the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority.
Enquiries:
|
Nuformix plc
|
|
|
Dr Dan Gooding, Executive
Director
|
Via IFC Advisory
|
|
Stanford Capital Partners Limited
|
|
|
Tom Price / Patrick Claridge
(Corporate Finance)
|
+44 (0) 20 3650 3650
|
|
Bob Pountney (Corporate
Broking)
|
+44 (0) 20 3650 3652
|
|
IFC
Advisory Limited
|
|
|
Tim Metcalfe
Zach Cohen
|
+44 (0) 20 3934 6630
nuformix@investor-focus.co.uk
|
About Nuformix
Nuformix is a pharmaceutical
development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug
forms, with improved physical properties, to develop new products
in new indications that are, importantly, differentiated from the
original (by way of dosage, delivery route or presentation), thus
creating new and attractive commercial opportunities. Nuformix has
a pipeline of preclinical assets with potential for significant
value and early licensing opportunities.
